News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,999 Results
Type
Article (39152)
Company Profile (283)
Press Release (648564)
Section
Business (203904)
Career Advice (1996)
Deals (35372)
Drug Delivery (89)
Drug Development (80854)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344648)
Policy (32450)
Tag
Academia (2530)
Alliances (49185)
Alzheimer's disease (1260)
Approvals (16059)
Artificial intelligence (145)
Bankruptcy (352)
Best Places to Work (11582)
Biotechnology (200)
Breast cancer (188)
Cancer (1373)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64707)
Collaboration (485)
Compensation (262)
COVID-19 (2541)
C-suite (109)
Data (1391)
Diabetes (175)
Diagnostics (6170)
Earnings (84895)
Employer resources (146)
Events (110014)
Executive appointments (396)
FDA (16784)
Funding (428)
Gene therapy (195)
GLP-1 (599)
Government (4333)
Healthcare (18694)
Infectious disease (2634)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16343)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (198)
Manufacturing (207)
Medical device (13212)
Medtech (13217)
Mergers & acquisitions (19194)
Metabolic disorders (459)
Neuroscience (1581)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1698)
Obesity (262)
Opinion (183)
Parkinson's disease (98)
Patents (120)
People (56463)
Phase I (20126)
Phase II (28499)
Phase III (21242)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (263)
Real estate (5890)
Regulatory (21679)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1467)
Startups (3562)
United States (15215)
Vaccines (564)
Weight loss (182)
Date
Today (102)
Last 7 days (566)
Last 30 days (2351)
Last 365 days (35261)
2024 (35102)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46542)
2018 (35019)
2017 (32110)
2016 (31483)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37273)
Australia (6087)
California (3824)
Canada (1454)
China (307)
Colorado (172)
Connecticut (177)
Europe (79832)
Florida (537)
Georgia (136)
Illinois (385)
Indiana (225)
Maryland (632)
Massachusetts (2970)
Michigan (174)
Minnesota (291)
New Jersey (1108)
New York (1089)
North Carolina (743)
Northern California (1698)
Ohio (146)
Pennsylvania (925)
South America (1092)
Southern California (1467)
Texas (552)
Utah (108)
Washington State (401)
687,999 Results for "glycomimetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
October 29, 2024
·
15 min read
Press Releases
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
November 6, 2024
·
3 min read
BioCapital
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
April 25, 2024
·
1 min read
Drug Development
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML.
June 4, 2024
·
9 min read
Business
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023.
March 27, 2024
·
9 min read
Drug Development
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics, Inc., a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML.
May 6, 2024
·
6 min read
Press Releases
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
October 29, 2024
·
2 min read
BioCapital
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET.
March 13, 2024
·
1 min read
BioCapital
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET.
February 26, 2024
·
1 min read
Drug Development
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company’s pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
May 29, 2024
·
4 min read
1 of 68,800
Next
